National Multiple Sclerosis Society

UAE Grants World's First Approval for Tolebrutinib, Breakthrough Oral Treatment for Progressive Multiple Sclerosis

- The Emirates Drug Establishment has approved Tolebrutinib, making the UAE the first country to authorize this oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). - Tolebrutinib represents a novel therapeutic approach as a Bruton's tyrosine kinase (BTK) inhibitor that directly targets disability progression by addressing chronic neuroinflammation in the brain and spinal cord. - The approval was based on a scientific study conducted in collaboration with the National Multiple Sclerosis Society, marking a significant advancement for patients with limited treatment options. - This breakthrough therapy specifically targets B cells and microglia within the central nervous system, offering the first treatment designed to slow disability progression independent of relapses.